IL-8 antibodies and methods of use thereof
Anti-IL-8 antibodies are developed to target IL-8 signaling, inhibiting tumor growth and reducing neutrophil and monocyte activation, addressing the need for therapeutic molecules in cancer and viral infections.
JP7765457B2Active Publication Date: 2025-11-06STELEXIS THERAPEUTICS LLC
1 Cites 0 Cited by
Patent Information
- Application Number
- JP2023508501
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-08-06
- Filing Date
- 2021-08-05
- Publication Date
- 2025-11-06
- Estimated Expiration
- 2041-08-05
AI Technical Summary
Technical Problem
There is a need for therapeutic molecules that target the deleterious effects of IL-8 in cancer and viral infections by modulating cell activation and migration.
Method used
Development of isolated anti-IL-8 antibodies with specific VH-VL pair sequences, including IgG, Fv, scFv, Fab, and other antibody fragments, designed to inhibit IL-8 signaling and reduce neutrophil and monocyte activation in the tumor microenvironment.
Benefits of technology
The anti-IL-8 antibodies effectively inhibit tumor formation and growth, reduce neutrophil and monocyte activation, and treat diseases associated with IL-8, including various cancers and viral infections.
✦ Generated by Eureka AI based on patent content.
Abstract
Described herein are anti-IL-8 antibodies, compositions thereof, and methods of use thereof. Anti-IL-8 antibodies may be useful in methods of inhibiting tumor formation or growth, or a combination thereof. Also described herein are methods of using anti-IL-8 antibodies for treating disease, where the disease may include cancer, tumor, or viral infection.
Need to check novelty before this filing date? Find Prior Art